MedTrace Logo

Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction

NCT04303377 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-11-21

No results posted yet for this study

Summary

This is a prospective, multi-centre, open label, randomised study of Phase II that enrolls patients hospitalized with a diagnosis of ST-elevation myocardial infarction (STEMI), comparing Evolocumab versus Standard of Care.

Conditions

  • ST-elevation Myocardial Infarction

Interventions

BIOLOGICAL

Evolocumab

Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)

Sponsors & Collaborators

  • Centro Cardiologico Monzino

    collaborator OTHER

  • Ospedale Bassini Cinisello Balsamo

    collaborator UNKNOWN

  • Azienda Ospedaliera Ordine Mauriziano di Torino

    collaborator OTHER

  • Ospedale Policlinico San Martino

    collaborator OTHER

  • Fondazione Poliambulanza Istituto Ospedaliero

    collaborator OTHER

  • Azienda Ospedaliera San Gerardo di Monza

    collaborator OTHER

  • Azienda Ospedaliera Sant'Anna e San Sebastiano

    collaborator OTHER

  • Azienda Ospedaliera, Ospedale Civile di Legnano

    collaborator OTHER

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2020-01-02
Completion
2020-07-24
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04303377 on ClinicalTrials.gov